Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis

Yi Ying Wu, Anthony J. Janckila, Chih Hung Ku, Cheng Ping Yu, Jyh Cherng Yu, Su Hui Lee, Hsin Yi Liu, Lung T. Yam, Tsu Yi Chao

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden. We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic markers of survival in BC patients with bone metastasis.Methods: We analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of TRACP 5b was calculated from data obtained from 15 patients with early BC.Results: Estrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p <0.0001). Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).Conclusions: We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is necessary to confirm these results.

Original languageEnglish
Article number158
JournalBMC Cancer
Volume10
DOIs
Publication statusPublished - Apr 23 2010
Externally publishedYes

Fingerprint

Bone Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Survival
Serum
Bone and Bones
Tartrate-Resistant Acid Phosphatase
Osteoclasts
Tumor Burden
Estrogen Receptors
Prospective Studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. / Wu, Yi Ying; Janckila, Anthony J.; Ku, Chih Hung; Yu, Cheng Ping; Yu, Jyh Cherng; Lee, Su Hui; Liu, Hsin Yi; Yam, Lung T.; Chao, Tsu Yi.

In: BMC Cancer, Vol. 10, 158, 23.04.2010.

Research output: Contribution to journalArticle

Wu, Yi Ying ; Janckila, Anthony J. ; Ku, Chih Hung ; Yu, Cheng Ping ; Yu, Jyh Cherng ; Lee, Su Hui ; Liu, Hsin Yi ; Yam, Lung T. ; Chao, Tsu Yi. / Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. In: BMC Cancer. 2010 ; Vol. 10.
@article{bc66d61c684f4a24ab1c575891309297,
title = "Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis",
abstract = "Background: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden. We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic markers of survival in BC patients with bone metastasis.Methods: We analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of TRACP 5b was calculated from data obtained from 15 patients with early BC.Results: Estrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p <0.0001). Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59{\%}) (p = 0.0015).Conclusions: We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is necessary to confirm these results.",
author = "Wu, {Yi Ying} and Janckila, {Anthony J.} and Ku, {Chih Hung} and Yu, {Cheng Ping} and Yu, {Jyh Cherng} and Lee, {Su Hui} and Liu, {Hsin Yi} and Yam, {Lung T.} and Chao, {Tsu Yi}",
year = "2010",
month = "4",
day = "23",
doi = "10.1186/1471-2407-10-158",
language = "English",
volume = "10",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis

AU - Wu, Yi Ying

AU - Janckila, Anthony J.

AU - Ku, Chih Hung

AU - Yu, Cheng Ping

AU - Yu, Jyh Cherng

AU - Lee, Su Hui

AU - Liu, Hsin Yi

AU - Yam, Lung T.

AU - Chao, Tsu Yi

PY - 2010/4/23

Y1 - 2010/4/23

N2 - Background: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden. We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic markers of survival in BC patients with bone metastasis.Methods: We analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of TRACP 5b was calculated from data obtained from 15 patients with early BC.Results: Estrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p <0.0001). Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).Conclusions: We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is necessary to confirm these results.

AB - Background: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden. We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic markers of survival in BC patients with bone metastasis.Methods: We analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of TRACP 5b was calculated from data obtained from 15 patients with early BC.Results: Estrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p <0.0001). Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).Conclusions: We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is necessary to confirm these results.

UR - http://www.scopus.com/inward/record.url?scp=77951144287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951144287&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-10-158

DO - 10.1186/1471-2407-10-158

M3 - Article

C2 - 20416078

AN - SCOPUS:77951144287

VL - 10

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 158

ER -